Drugs / ZL-2102
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02397005 Comparator | Mar 2015 → Apr 2016 | asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis | Zai Lab Pty. Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-2102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02397005 ↗ |
| Action | Inhibit | “A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).” NCT02397005 ↗ |
| Route | Oral | “ascending single oral doses” NCT02397005 ↗ |